1. Hauspy J, Nevin A, Harley I, et al. Paraneoplastic syndrome in vaginal melanoma: a case report and review of the literature. Int J Gynecol Cancer 2007; 17: 1159-63.
2.
Mondragón JD, Jiménez-Zarazúa O, Vélez-Ramírez LN, et al. Paraneoplastic opsoclonus-myoclonus syndrome secondary to melanoma metastasis form occult primary cancer. Case Rep Neurol 2019; 11: 66-79.
3.
Dresco F, Aubin F, Deveza E, et al. Paraneoplastic opsoclonus-myoclonus syndrome preceding a mucosal malignant melanoma. Acta Derm Venereol 2019; 99: 337-8.
4.
Lee SF, Atkinson V. A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma. Melanoma Res 2016; 26: 425-8.
5.
Jiménez-Zarazúa O, Vélez-Ramírez LN, Alcocer-León M, et al. Paraneoplastic cerebellar degeneration secondary to BRAF mutant melanoma metastasis from an occult primary cancer. Case Rep Oncol 2020; 13: 633-42.
6.
Rovere RK, Pires de Souza ME, Hilgert SF, et al. Melanoma metastasis to the gastric mucosa preceded by guillain-barré as a paraneoplastic syndrome. Gastrointest Cancer Res 2013; 6: 150-1.
7.
Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol 2006; 253: 942-3.
8.
Becquart C, Ryckewaert G, Desmedt E, et al. Encéphalite limbique : une nouvelle manifestation auto-immune paranéoplasique associée au mélanome métastatique ? [Limbic encephalitis: a new paraneoplastic auto-immune manifestation associated with metastatic melanoma?]. Ann Dermatol Venereol 2013; 140: 278-81.
9.
Valpione S, Zoccarato M, Parrozzani R, et al. Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma. J Neurol Sci. 2013; 335: 210-2.
10.
Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016; 2016: bcr2016215012.
11.
Williams SL, McDonald HR, Jumper JM, et al. Paraneoplastic vitelliform retinopathy in a patient with treated choroidal melanoma. Retin Cases Brief Rep 2014; 8: 269-72.
12.
Nagiel A, Rootman DB, McCannel TA. Paraneoplastic vitelliform maculopathy in the setting of choroidal melanoma: evolution over one year. Retin Cases Brief Rep 2017; 11 Suppl 1: S7-10.
13.
Sotodeh M, Paridaens D, Keunen J, et al. Paraneoplastic vitelliform retinopathy associated with cutaneous or uveal melanoma and metastases. Klin Monbl Augenheilkd 2005; 222: 910-4.
14.
Evoy F, Lafortune J. First case of melanoma-associated retinopathy with conjunctival melanoma. Can J Ophthalmol 2020; 55: e153-5.
15.
Navarrete-Dechent C, Monnier J, Marghoob NG, et al. Bilateral diffuse uveal melanocytic proliferation with multifocal diffuse integumentary melanocytic proliferation paraneoplastic syndrome: a case report. Australas J Dermatol 2021; 62: 386-9.
16.
Kellner U, Bornfeld N, Foerster MH. Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol 1995; 79: 746-52.
17.
Meier PG, Ambresin A, Thirkill CE, et al. Paraneoplastic vitelliform retinopathy secondary to metastatic melanoma. Klin Monbl Augenheilkd 2015; 232: 587-9.
18.
Krema H, Simpson R, Altomare F, Ebadi M. Paraneoplastic vitelliform retinopathy in metastatic cutaneous melanoma. Retin Cases Brief Rep 2010; 4: 246-50.
19.
Rahimi M, Navajas EV, Sarraf D. Paraneoplastic vitelliform maculopathy associated with metastatic melanoma. Retin Cases Brief Rep 2018; 12 Suppl 1: S102-4.
20.
Kiratli H, Thirkill CE, Bilgiç S, et al. Paraneoplastic retinopathy associated with metastatic cutaneous melanoma of unknown primary site. Eye (Lond) 1997; 11: 889-92.
21.
Schoenberger SD, Kim SJ, Lavin P. Paraneoplastic optic neuropathy from cutaneous melanoma detected by positron emission tomographic and computed tomographic scanning. Arch Ophthalmol 2012; 130: 1223-5.
22.
Nieuwendijk TJ, Hooymans JM. Paraneoplastic vitelliform retinopathy associated with metastatic choroidal melanoma. Eye (Lond) 2007; 21: 1436-7.
23.
Heberton M, Azher T, Council ML, Khanna S. Metastatic cutaneous melanoma presenting with melanoma-associated retinopathy. Dermatol Surg 2019; 45: 606-7.
24.
Tian JJ, Coupland S, Karanjia R, Sadun AA. Melanoma-associated retinopathy 28 years after diagnosis. JAMA Ophthalmol 2017; 135: 1276-77.
25.
Audemard A, de Raucourt S, Miocque S, et al. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology 2013; 227: 146-9.
26.
Morimoto T, Hayashida S, Yamasaki K, et al. Paraneoplastic neuromyelitis optica spectrum disorder associated with malignant melanoma: a case report. Thorac Cancer 2021; 12: 1775-9.
27.
Machida S, Ohguro H, Tateda M, et al. Melanoma-associated retinopathy associated with intranasal melanoma. Doc Ophthalmol 2011; 122: 191-7.
28.
Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology 1994; 101: 1236-43.
29.
Khurana RN, Wieland MR, Boldrey EE, et al. Vitelliform retinopathy in metastatic cutaneous melanoma with choroidal involvement. Arch Ophthalmol 2011; 129: 1498-9.
30.
Rappoport D, Leiba H. Presumed melanoma-associated retinopathy (MAR): a presenting sign of primary small intestinal melanoma? Int Ophthalmol 2012; 32: 387-91.
31.
Potter MJ, Thirkill CE, Dam OM, et al. Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy. Ophthalmology 1999; 106: 2121-5.
32.
Okel BB, Thirkill CE, Anderson K. An unusual case of melanoma-associated retinopathy. Ocul Immunol Inflamm 1995; 3: 121-8.
33.
Khaddour K, Khanna S, Ansstas M, et al. Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma. Cancer Immunol Immunother 2021; 70: 2497-502.
34.
Ng CC, Alsberge JB, Qian Y, et al. Vogt-Koyanagi-Harada-like uveitis followed by melanoma-associated retinopathy with focal chorioretinal atrophy and choroidal neovascularization in a patient with metastatic cutaneous melanoma. Retin Cases Brief Rep 2023; 17: 18-22.
35.
Kloos L, Sillevis Smitt P, Ang CW, et al. Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma. J Neurol Neurosurg Psychiatry 2003; 74: 507-9.
36.
Liozon E, Ly KH, Vidal-Cathala E, Fauchais AL. Pseudomaladie de Still et néoplasie : une observation de mélanome et revue de la littérature [Adult-onset Still’s disease as a manifestation of malignancy: report of a patient with melanoma and literature review]. Rev Med Interne 2014; 35: 60-4.
37.
Perrotta FM, Scriffignano S, Fatica M, et al. Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab. Reumatismo 2020; 72: 178-81.
38.
Jouary T, Gracia C, Lalanne N, et al. Rapidly lethal dermatomyositis associated with metastatic melanoma. J Eur Acad Dermatol Venereol 2008; 22: 399-401.
39.
Veyssier-Belot C, Zuech P, Lumbroso-Le Rouic L, et al. Fasciite à éosinophiles révélant l’extension métastatique d’un mélanome de la choroïde : un syndrome paranéoplasique [Eosinophilic fasciitis and metastatic choroïdal melanoma: a paraneoplastic syndrome?]. Rev Med Interne 2008; 29: 1013-6.
40.
Rea A, Anderson A, Moshiri A, et al. Eosinophilic fasciitis as a paraneoplastic syndrome in melanoma. JAAD Case Rep 2021; 17: 49-51.
41.
Tu J, Von Nida J. Metastatic malignant melanoma and dermatomyositis: a paraneoplastic phenomenon. Australas J Dermatol 2011; 52: e7-10.
42.
Thoelke A, Schmid HP, Figl R, et al. Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma. Eur J Dermatol 2006; 16: 428-30.
43.
Schiller M, Böhm M, Hensen P, et al. Dermatomyositis associated with malignant melanoma--a marker of poor prognosis? J Am Acad Dermatol 2006; 54: 221-6.
44.
Fredeau L, Bohelay G, Shourick J, et al. Paraneoplastic neutrophilic leukaemoid reaction in a patient with melanoma: association between tumour volume and leucocytosis. Br J Dermatol 2020; 183: 579-80.
45.
Rule SA, Waterhouse P, Costello C, Retsas S. Paraneoplastic eosinophilia in malignant melanoma. J R Soc Med 1993; 86: 295.
46.
Gambichler T, Stockfleth E, Susok L. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy. J Immunother Cancer 2018; 6: 113.
47.
De Giorgi V, Gemignani A, Scarfì F, et al. Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon? Melanoma Res 2022; 32: 63-6.
48.
Savarese I, Grazzini M, Gori A, et al. Trichilemmal cystis in metastatic melanoma: a case report. Exp Oncol 2017; 39: 86-7.
49.
Schaeppi H, Bauer JW, Hametner R, et al. A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol 2001; 144: 1249-54.
50.
Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013; 23: 498-501.
51.
Siedek V, Schuh T, Wollenberg A. Leser-Trelat sign in metastasized malignant melanoma. Eur Arch Otorhinolaryngol 2009; 266: 297-9.
52.
Gori N, Esposito I, Del Regno L, et al. Leser-Trélat sign as a rare manifestation of cutaneous melanoma. Dermatol Rep 2020; 12: 8665.
53.
Hirner J. Subacute cutaneous lupus erythematosus with a possible paraneoplastic association with melanoma. BMJ Case Rep 2019; 12: e230558.
54.
Kolominsky J, Poklepovic A, Syed A, et al. Granulomatous cardiomyopathy presenting as a paraneoplastic syndrome in metastatic melanoma. CJC Open 2023; 5: 713-6.
55.
Thompson MA, Warner NB, Hwu WJ. Hypertrophic osteoarthropathy associated with metastatic melanoma. Melanoma Res 2005; 15: 559-61.
56.
Sultan-Bichat N, Vuiblet V, Winckel A, et al. Glomérulonéphrite extramembraneuse paranéoplasique au cours d’un mélanome [Membranous glomerulonephritis as a paraneoplastic manifestation of melanoma]. Ann Dermatol Venereol 2011; 138: 46-9.
57.
Gambichler T, Strutzmann S, Tannapfel A, Susok L. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade. BMC Cancer 2017; 17: 327.
58.
Hobbs CB, Miller AL. Review of endocrine syndromes associated with tumours of non-endocrine origin. J Clin Pathol 1966; 19: 119-27.
59.
Bilynsky BT, Dzhus MB, Litvinyak RI. The conceptual and clinical problems of paraneoplastic syndrome in oncology and internal medicine. Exp. Oncol 2015; 37: 82-8.
60.
Dimitriadis GK., Angelousi A., Weickert MO, et al. Paraneoplastic endocrine syndromes. Endocr Relat Cancer 2017; 24: R173-90.
61.
Maverakis E, Goodarzi H, Wehrli LN, et al. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol 2012; 42: 135-44.
62.
Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin 2009; 59: 73-98.
63.
Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS. Cutaneous manifestations of internal malignancy. Curr Probl Surg 2010; 47: 384-445.
64.
Vyas R, Selph J, Gerstenblith MR. Cutaneous manifestations associated with melanoma. Semin Oncol 2016; 43: 384-9.
65.
Iyer JG, Parvathaneni K, Bhatia S, et al. Paraneoplastic syndromes (PNS) associated with merkel cell carcinoma (MCC): a case series of 8 patients highlighting different clinical manifestations. J Am Acad Derm 2016; 75: 541-7.
66.
Jacobson DM. Paraneoplastic diseases of neuro-ophthalmology interest. In: Walsh & Hoyt’s Clinical Neuro-ophthalmology. Miller NR, Newman NJ, eds. Baltimore: Williams & Wilkins 1998; 2497-551.
67.
Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristic of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21: 173-87.
68.
Chan C, O’Day J. Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 2001; 29: 235-8.
69.
Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 1999; 117: 471-7.
70.
Dalakas MC. The use of intravenous immunoglobulin for neuro- logic diseases. Neurology 1998; 51 (6 suppl 5): S1-45.
71.
Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52: 629-32.
72.
Visser LH, Schmitz PI, Meulstee J, et al. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 1999; 53: 598-604.
73.
Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo- controlled study. Neurology 2000; 55: 1256-62.
74.
Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999; 106: 2136-43.
75.
Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin.
76.
Am J Ophthalmol 1999; 127: 545-9.
77.
Letko E, Bhol K, Foster CS, et al. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology 2000; 107: 1524-8.
78.
Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2: 22-30.
79.
Honnorat J. New findings in adult opsoclonus-myoclonus syndrome. JAMA Neurol 2016; 73: 381-2.
80.
Armangué T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016; 73: 417-24.
81.
Honnorat J. New findings in adult opsoclonus-myoclonus syndrome. JAMA Neurol 2016; 73: 381-2.
82.
Berger JR, Mehari E. Paraneoplastic opsoclonus-myoclonus secondary to malignant melanoma. J Neurooncol 1999; 41: 43-5.
83.
Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syn- drome in an adult with malignant melanoma. J Neurol 2006; 253: 942-3.
84.
Vedeler CA, Antoine JC, Giometto B, et al. Paraneoplastic neurological syndromes. In: European Handbook of Neurological Management. Gilhus NE, Barnes MP, Brainin M, editors. Singapore: Blackwell Publishing Ltd; 2011; 447-57.
85.
Joubert B, Rostásy K, Honnorat J. Immune-mediated ataxias. Handb Clin Neurol 2018; 155: 313-32.
86.
Schiller M, Bohm M, Hensen P, et al. Dermatomyositis associ- ated with malignant melanoma – a marker of poor prognosis? J Am Acad Dermatol 2006; 54: 221-6.
